Skip to main content

Specialty Pharmacy

  • H.D. Smith appoints Bill Williams as CFO

    SPRINGFIELD, Ill. — Pharmaceutical wholesaler H.D. Smith has appointed Bill Williams as CFO, the company said Wednesday.

    Williams, who has worked at such companies as Kraft Foods, Allied Signal and Martin Brower Co., most recently worked as a partner in Tatum LLC's Chicago office.

  • BioScrip's sales, profits increase in Q4, FY2011

    ELMSFORD, N.Y. — Specialty pharmacy provider BioScrip had sales of $483.3 million in fourth quarter 2011 and $1.8 billion in fiscal year 2011, the company said Friday.

    The company's fourth-quarter sales marked an increase of $32.9 million, while the sales for the year were $200 million over fiscal year 2010. Meanwhile, the company had profits of $6.7 million for the quarter and $7.9 million for the year.

  • FDA committee to discuss anti-NGF drug class at meeting

    WASHINGTON — A Food and Drug Administration panel will meet Monday to discuss a class of drugs designed to treat chronic painful conditions that currently are under development and the safety issues possibly related to the drugs.

  • Q&A: Streamlining specialty

    In January, specialty pharmacy group contracting organization Armada Health Care introduced ApproveRx, a Web-based system that it says will greatly streamline the prior authorization process and already has been adopted by Amber Pharmacy. Meanwhile, the company also is gearing up for the Armada Summit at the Wynn Las Vegas Hotel in May. Recently, Drug Store News spoke with Armada CEO Larry Irene about these recent developments.


    DSN: How did Armada develop the ApproveRx 
system? 


  • MTM fights diabetes on the front lines

    The number of patients with diabetes is not decreasing any time soon, and one of the most important fronts in the battle lies at the pharmacy counter.


  • Prime Therapeutics, Merck KGaA subsidiary enter contractual agreement over MS drug

    ST. PAUL, Minn. — A pharmacy benefit manager and the U.S. subsidiary of a German drug maker have made a deal concerning a drug for multiple sclerosis.

  • Drug price inflation outpaces general inflation, AARP study finds

    WASHINGTON — Prices for generic drugs may be dropping, but increases in branded and specialty drug prices have offset those decreases, according to a new study.

    The study, conducted by AARP's Public Policy Institute, found that the cumulative change in drug prices from 2005 to 2009 was almost double the rate of inflation. As a result, the average annual cost of drug therapy continued to rise.

  • FDA turns down Eisai drug application

    WOODCLIFF LAKE, N.J. — The Food and Drug Administration has declined to approve a drug made by Eisai for leukemia in certain elderly patients, the drug maker said.

    Eisai said the FDA delivered it a complete response letter for the chemotherapy drug Dacogen (decitabine) in patients ages 65 years and older with acute myeloid leukemia who are not candidates for induction therapy. The FDA delivers a complete response letter when questions remain about an regulatory application that preclude approval, usually due to insufficient clinical trial data.

X
This ad will auto-close in 10 seconds